Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose safety, tolerability and PK study of MK-6024 in healthy Japanese males
jRCT2031210703Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of suvorexant in metabolic dysfunction-associated steatohepatitis (MASH) (5 arms), sponsored by Merck & Co. Started Apr 2022; status: completed.
02
Drugs
suvorexant
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2031210703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210703.